Author

Raúl V. Durán

Consejo Superior de Investigaciones CientíficasORCID 0000-0002-2249-9215Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Approach:mechanistic / dynamical model· 1 Assay:proteomics· 1

Frequent Co-Authors

Gema Moreno‐BuenoiD· 2 shared Ignacio G. López-Cepero· 2 shared Macarena Morillo‐HuescaiD· 2 shared Mercedes ToméiD· 2 shared Ana Reina-Bando· 1 shared Colin K. W. WattsiD· 1 shared Elena Sánchez-Escabias· 1 shared G. Vignir HelgasoniD· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Gema Moreno‐BuenoORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Asparagine endopeptidase promotes radioresistance in breast cancer through ATR pathway modulation

Macarena Morillo‐Huesca, Ignacio G. López-Cepero, Ryan Conesa-Bakkali, Mercedes Tomé, Colin K. W. Watts, Pablo Huertas, Gema Moreno‐Bueno, Raúl V. Durán, Jonathan Martínez‐Fábregas

This study identifies AEP's role in promoting radioresistance in breast cancer by modulating the ATR pathway and PPP1R10 levels, showing AEP-high/ATR-low as a biomarker for radioresistant patients.

Journal of Experimental & Clinical Cancer Research · Feb 26, 2025Peer-reviewedCancer Biology

FGFR1 inhibition prevents metabolic adaptation associated with therapy resistance in glioblastoma

Laura Zarzuela, Ignacio G. López-Cepero, Kevin M. Rattigan, Elena Sánchez-Escabias, Macarena Morillo‐Huesca, Ana Reina-Bando, Sara S. Oltra, Jesús María Sierra-Párraga, María Ceballos-Chávez, Vivian Capilla‐González, Gema Moreno‐Bueno, Piedad del Socorro Murdoch, José C. Reyes, G. Vignir Helgason, Mercedes Tomé, Raúl V. Durán

This study identifies FGFR1 as a key driver of TMZ resistance in GBM through metabolic rewiring and cell cycle regulation, showing that FGFR1 inhibition restores TMZ sensitivity in preclinical models.

bioRxiv · Jan 11, 2025 · PreprintCancer Biology